Next-generation sequencing (NGS) is a powerful, high-throughput DNA sequencing technology. Millions or billions of DNA fragments can be sequenced in parallel, in a single sequencing run. NGS is revolutionizing modern science and healthcare.
Everyone’s disease is different because the genetics of each individual is different. Genetic variation often determines the success of treatment. The results from these NGS tests will enable a physician to make the best informed choices and to ensure the best possible outcome for the patient.
Bio-Connect Diagnostics provides Invivoscribe's
streamlined, one-step, next-generation sequencing (NGS) library kits for clonality detection and Minimal Residual Disease (MRD) analysis which are available for both Thermo Fisher Scientific® Ion PGM and Illumina® MiSeq® platforms. They include comprehensive bioinformatics software.
Invivoscribe gold standard B- and T-cell PCR-based capillary testing reagents, developed in partnership with studies conducted by the EuroClonality BIOMED-2 concerted action, were commercialized by them and are manufactured per cGMP.